Celldex Therapeutics (CLDX) Operating Expenses (2010 - 2026)

Celldex Therapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $84.4 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 33.13% year-over-year to $84.4 million; the TTM figure through Mar 2026 stood at $309.9 million (up 37.89% YoY), while the FY2025 annual figure was $288.9 million, up 42.96% from the prior year.
• Operating Expenses was $84.4 million for Q1 2026 at Celldex Therapeutics, down from $87.3 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $87.3 million in Q4 2025 to a low of $23.4 million in Q1 2022.
• Historically, Operating Expenses has averaged $50.3 million across 5 years, with a median of $48.8 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Operating Expenses surged 116.07% in 2022, then retreated 8.44% in 2023.
• A 5-year view of Operating Expenses shows it stood at $29.5 million in 2022, then jumped by 75.46% to $51.8 million in 2023, then increased by 10.52% to $57.2 million in 2024, then surged by 52.57% to $87.3 million in 2025, then retreated by 3.24% to $84.4 million in 2026.
• The last three Operating Expenses figures came in at $84.4 million (Q1 2026), $87.3 million (Q4 2025), and $73.6 million (Q3 2025), per Business Quant data.